2018 年年度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2018 年年度报告 1 / 197 2018 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司拟以2018年12月31日公司总股本13,000万股为基数，向全体股东每10股派发 现金红利人民币1.6元（含税），共计派发现金红利2,080万元；同时以资本公积转增 股本方式向全体股东每10股转增3股，合计转增3900万股，转增后公司总股本将增加 至16,900万股。 以上利润分配预案尚需公司2018年年度股东大会审议通过。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质 承诺，请投资者注意风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司生 ...

2018 年第三季度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2018 年第三季度报告 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 9 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | | 本报告期末比上年 度末增减(%) | | --- | --- | --- | --- | --- | | 总资产 | 842,849,977.1 ...

公司代码：603880 公司简称：南卫股份 重要提示 三、 本半年度报告未经审计。 四、 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员） 王亚华声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质 承诺，请投资者注意风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 江苏南方卫材医药股份有限公司 2018 年半年度报告 2018 年半年度报告 十、 其他 □适用 √不适用 2 / 135 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 二、 公司全体董事出席董事会会议。 | 第一节 | 释义 4 | | --- | --- | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 公司业务概要 8 | | 第四节 | 经营情况的讨论与分析 13 | | 第五节 | 重要事项 ...

2018 年第一季度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2018 年第一季度报告 1 / 19 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 3 / 19 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度 末增减(%) 总资产 800,290,545.30 822,964,834.25 -2.76 归属于上市公司 股东的净资产 544,018,287.07 531,813,887.73 2.29 年初至报告期末 上年初至上年报告 期末 比上年同期增减(%) 经营活动产生的 现金流量净额 9,492,642.49 17,348,204.80 -45.28 年初至报告期末 上年初至上年报告 期末 比上年同期增减（%） 营业收入 119,120,407.54 105,742,587.57 12.65 归属于上市公司 股东的净利润 12,204,399.33 11,5 ...

Financial Performance - The company's operating revenue for 2017 was RMB 488.71 million, representing a 10.01% increase compared to RMB 444.24 million in 2016[21] - The net profit attributable to shareholders of the listed company decreased by 8.42% to RMB 47.60 million in 2017 from RMB 51.98 million in 2016[21] - The net profit after deducting non-recurring gains and losses was RMB 45.38 million, down 11.00% from RMB 50.99 million in the previous year[21] - The net cash flow from operating activities was RMB 49.24 million, a significant decrease of 50.44% compared to RMB 99.35 million in 2016[21] - Basic earnings per share decreased by 17.39% to CNY 0.57 compared to the previous year[22] - The weighted average return on equity dropped by 7.92 percentage points to 13.14%[22] - The gross profit margin for the industrial segment was 26.43%, a decrease of 3.17 percentage points compared to the previous year[57] - The company reported a net cash flow from financing activities increased significantly to ¥216,807,123.25, driven by the initial public offering[69] - The company achieved operating revenue of RMB 488.71 million, an increase of RMB 44.47 million or 10.01% compared to the previous year[51] - The net profit attributable to shareholders decreased by RMB 4.38 million, down 8.42% year-on-year, totaling RMB 47.60 million[51] Assets and Liabilities - The total assets of the company increased by 59.32% to RMB 822.96 million at the end of 2017, up from RMB 516.55 million at the end of 2016[21] - The net assets attributable to shareholders of the listed company rose by 110.24% to RMB 531.81 million at the end of 2017, compared to RMB 252.96 million at the end of 2016[21] - Total liabilities rose from RMB 259.87 million to RMB 285.40 million, resulting in a decrease in the debt-to-asset ratio from 50.31% to 34.68%[175] - The company’s accounts payable increased by 56.01% to RMB 88,742,453.98, reflecting higher purchase volumes[72] - Monetary funds rose by 174.29% to RMB 268,328,947.84, attributed to stock issuance and inventory increases[72] Market and Industry Insights - The medical device market in China is projected to exceed RMB 700 billion by 2020, with an annual growth rate of over 10% expected in the next decade[35] - The medical device industry in China saw a revenue growth rate of over 10% from 2010 to 2015, with 2015 revenue reaching RMB 241.4 billion, a year-on-year increase of 13%[36] - The medical dressing market in China has an annual output value of RMB 30 billion, growing at a rate of 20%-30% per year[76] - The wound care market in China is experiencing growth, with a significant increase in demand for advanced wound dressings that can shorten healing time and improve patient comfort[77] - The domestic market for topical analgesic patches is rapidly expanding, driven by a large patient population suffering from musculoskeletal pain, with over 200 manufacturers currently producing various types of patches[79] Research and Development - The company emphasizes technological research and development, achieving leading positions in various technologies such as high water absorption hydrogel preparation and EVA film wound dressing technology[39] - The company has developed high-end functional dressings and emergency kits, enhancing its product line and expected profitability[40] - The company has invested heavily in R&D, focusing on improving production efficiency and product quality, with significant advancements in high-speed adhesive plaster machines and automatic equipment for medical tape production[90] - The company’s research and development expenses amounted to RMB 19.91 million, reflecting a 5.79% increase year-on-year[54] - Major R&D projects include the development of a new type of transdermal patch with a cumulative investment of ¥3,900,000 and a solvent-free adhesive patch with ¥10,372,988.78 invested[96] Product and Market Strategy - The company primarily engages in the research, production, and sales of transdermal products, medical adhesive tapes, and emergency kits[28] - The company’s main products include band-aids, medical tapes, and sports protection products, with a focus on innovation in transdermal delivery systems[28] - The company primarily operates under the ODM model and is increasing efforts in developing its own brand products, focusing on first aid kits, sports protection products, and nursing products[32] - The company has established partnerships with several hospitals and pharmaceutical groups in China, enhancing its sales network across regions such as Beijing, Shandong, and Zhejiang[49] - The company plans to enhance R&D efficiency and reduce risks by integrating its technological and industrial resources, collaborating with universities and research institutions[92] Shareholder and Governance - The company has established a differentiated cash dividend policy, ensuring that cash dividends account for at least 25% of distributable profits when conditions allow[125] - The profit distribution plan for 2017 is subject to approval at the annual shareholders' meeting[131] - The company has committed to protecting the rights of minority shareholders during the profit distribution process[128] - The controlling shareholder, Li Ping, committed to vote in favor of the company's share repurchase plan at the upcoming shareholders' meeting[136] - The company guarantees the authenticity, accuracy, and completeness of its IPO documents, with legal responsibility for any misrepresentation[143] Operational Efficiency - The company has implemented a cost control system across procurement, production, sales, logistics, and after-sales service, effectively reducing production costs and improving profitability[45] - The company has improved production automation and introduced advanced equipment, resulting in increased production efficiency and product quality, particularly in the adhesive bandage and ointment sectors[46] - The company has established a strong management team with extensive experience, ensuring effective governance and operational management[42] - The company has established a comprehensive training management system to ensure effective training outcomes[200] - The company emphasizes a performance-linked compensation structure, aligning salaries with profitability and promoting value creation[199] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[191] - New product launches are expected to contribute an additional 200 million in revenue in the upcoming year[191] - The company plans to enhance its production capacity with the new medical adhesive dressing project, targeting an annual production capacity of 3 billion adhesive bandages and 2.6 million square meters of medical adhesive tape[116] - The company is considering strategic acquisitions to enhance its market position, with a target of identifying at least two potential candidates[191] - The company aims to achieve a revenue target of 500 million yuan and a net profit of 49 million yuan for the year 2018[115]

2017 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | | 上年度末 | | 本报告期末比上年 度末增减(%) | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 总资产 | 799,173,598.07 | | 516,552,378.80 | | 54.71 | | | | 归属于上市公司股东的净资产 | 525,329,664.32 | | 252,958,457.33 | | 107.67 | | | | | 年初至报告期末 | | 上年初至上年报告 | | 比上年同期增减(%) | | | | | （1-9 | 月） | 期末（1-9 | 月） | | | | | 经营活动产生的现金流量净额 | 45,644,548.08 | | 56,410,301.72 | | -19.08 | | | | | 年初至报告期末 | | 上年初至上年报告 | | 比上年同期增减 | | | | | （1-9 | 月） | 期末（1-9 | 月） | （%） | | | | 营 ...